Eliglustat for treating type 1 Gaucher disease

Equality Impact Assessment (Guidance development) (PDF 235 KB)

Final evaluation determination

Final evaluation determination document (PDF 556 KB)

Committee papers (PDF 2.56 MB)

Public committee slides (PowerPoint 808 KB)

Evaluation consultation

Evaluation consultation document (PDF 219 KB)

Evaluation consultation document (PDF 13.27 MB)

Public committee slides (PDF 549 KB)

Final scope (PDF 101 KB)

Final matrix (PDF 99 KB)

NICE's response to comments on the draft scope and provisional matrix (PDF 409 KB)

Equality impact assessment (Scoping) (PDF 121 KB)

Gaucher disease type 1 - eliglustat: final scope (PDF 98 KB)

Gaucher disease type 1 - eliglustat: final matrix (PDF 99 KB)

Gaucher disease type 1 - eliglustat: NICE's response to consultee and commentator comments on the draft scope and provisional matrix (PDF 372 KB)

Gaucher disease (type 1) - eliglustat: appendix B - draft scope for consultation (pre-referral) - November 2013 (PDF 230 KB)

Gaucher disease (type 1) - eliglustat: appendix C - provisional matrix (pre-referral) - November 2013 (PDF 149 KB)